Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Ann Oncol. 2023 Jul 1;34(9):772–782. doi: 10.1016/j.annonc.2023.06.009

Figure 3. Time to initiation of cytotoxic chemotherapy at IA2 in the BRCA1/2 subgroup.

Figure 3.

AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; IA2, second interim analysis; NE, not evaluable; NIRA, niraparib; PBO, placebo. aNominal P value.